Category > Business

Merck's 2Q Net Drops on Higher Costs, Charges
Despite big revenue jump, Merck posts big 2Q profit drop on higher costs, lower equity incomeMerck- Business- Revenue- Allegedly Unethical Firms- Merck &Co
Source: ABC

EADS Raises Outlook Despite Drop in Q2 Profit
Airbus parent EADS raises hopes for the full year, even as it reports decline in net profitAirbus- EADS- Boeing- Technology- History
Source: ABC

US Gas Stations: Stay BP or Change Name to Amoco?
US gas stations: Stay BP and its tainted image since Gulf oil spill or change name to Amoco?Amoco- BP- Business- Energy- Environment
Source: ABC

Newell Rubbermaid 2Q Profit Rises, Revenue Mixed
Newell Rubbermaid 2Q profit rises 23 pct, boosts full-year earnings outlook excluding itemsNewell Rubbermaid- Taxation- Business- Low Income Taxpayers- Graco
Source: ABC

Hitachi Bursts Back To Profit
Hitachi swung back to a profit in the last quarter as a recovery in demand for cars and consumer electronics lit a fire under several of its businesses.
Source: Wall Street Journal

Qualcomm in India Broadband Venture
Qualcomm is forming a joint venture with India's Global Holding and Tulip Telecom to build a network for offering wireless broadband services.
Source: Wall Street Journal

Exxon in Talks on China Gas Field
Exxon Mobil is in talks with PetroChina to jointly explore and develop an unconventional gas block in the Ordos basin in northern China.
Source: Wall Street Journal

Carlyle Sets First Close of China Fund
Carlyle Group announced the first closing of its landmark Chinese-currency-denominated fund after raising the equivalent of $350 million from a group of government and private-sector investors led by an arm of the Beijing city government.
Source: Wall Street Journal

Audi Sees Growth in China, U.S.
Audi reported its first-half net profit nearly doubled and said it is looking for strong growth in China and the U.S.
Source: Wall Street Journal

Merck's Profit Falls 52%
Pharmaceutical giant Merck said its earnings dropped 52%, weighed down by acquisition and other charges and weaker sales of key drugs.
Source: Wall Street Journal